Valneva SE (GB:0OB3)
LSE:0OB3
0OB3 Stock Chart & Stats
€2.81
-€0.07(-3.26%)
At close: 4:00 PM EST
€2.81
-€0.07(-3.26%)
Day’s Range― - ―
52-Week Range€2.26 - €5.42
Previous CloseN/A
Volume6.19K
Average Volume (3M)106.96K
Market Cap
€482.88M
Enterprise Value€580.48M
Total Cash (Recent Filing)€109.65M
Total Debt (Recent Filing)€207.25M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
May 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding172,213,490
10 Day Avg. Volume86,772
30 Day Avg. Volume106,960
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.70Price Target Upside174.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€165.46M
Bulls Say, Bears Say
Bulls Say
Recurring Commercial Vaccine SalesConsistent, growing sales of IXIARO and product sales concentration provide a durable revenue base tied to government and travel-market demand. Stable product revenues support gross margins and manufacturing scale, reducing reliance on one-off milestones over the medium term.
Regulatory Progress And Pipeline ValidationNew authorizations for IXCHIQ and positive data for chikungunya and VLA1601 materially expand addressable markets and lower development risk. These approvals strengthen commercial optionality across territories, improving long-term revenue potential and partner negotiation leverage.
Strategic Partnerships And Commercialization SupportDistribution agreements and partner funding shift commercialization costs and execution risk to experienced partners, speeding market access while conserving Valneva resources. Strategic partners strengthen go-to-market reach and can stabilize revenue recognition patterns over time.
Bears Say
Meaningful Leverage And Weakened EquityA debt-heavy capital structure reduces financial flexibility and raises refinancing and interest-rate exposure. With equity erosion, the company is more reliant on external funding; sustained operating underperformance could force dilutive financings or constrain strategic investments over the medium term.
Ongoing Negative Operating Cash FlowPersistent negative operating and free cash flow imply ongoing cash burn despite improvements. Continued reliance on financing limits reinvestment in R&D and commercial expansion and raises the probability of further liquidity actions until operating cash flow turns sustainably positive.
Regulatory Setback: IXCHIQ U.S. SuspensionThe U.S. suspension removes a major commercial market and introduces a multi-month regulatory overhang. Uncertain timing from the FDA hampers revenue visibility, delays scale-up benefits, and increases downside risk to partner payouts and commercial momentum until approval status is fully resolved.
Valneva News
0OB3 FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest share price was €2.26 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €482.88M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Mar 18, 2026. The company reported -€0.299 earnings per share for the quarter, missing the consensus estimate of -€0.155 by -€0.144.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Undervalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.07.
How many shares outstanding does Valneva SE have?
Valneva SE has 172,213,490 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.299 in its last earnings report, missing expectations of -€0.155. Following the earnings report the stock price went up 3.768%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in GB:0OB3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
0OB3 Stock 12 Month Forecast
Average Price Target
€7.70
▲(174.02% Upside)
Technical Analysis
Options Prices
Currently, No data available
---